Products for Research Use Only

Hyaluronidase (human recombinant)

CAT: 0804-HY-108903Size: 150 UDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-108903Size:150 U
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Hyaluronidase (human recombinant) (Vorhyaluronidase alfa; rHuPH 20) is an enzyme that catalyzes the degradation of hyaluronic acid. Hyaluronidase (human recombinant) is used to improve the absorption and dispersal of parenteral fluids, medications, and contrast media[1].
CAS Number
37326-33-3
Product Name Alternative
Vorhyaluronidase alfa; rHuPH 20
UNSPSC
12352204
Hazard Statement
H302, H315, H319, H335
Target
Biochemical Assay Reagents; Glycosidase
Type
Enzyme
Related Pathways
Metabolic Enzyme/Protease; Others
Applications
Cancer-programmed cell death
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/hyaluronidase-human-recombinant.html
Purity
0
Solubility
10 mM in DMSO
Smiles
[Hyaluronidase(humanrecombinant)]
Precautions
H302, H315, H319, H335
References & Citations
[1]E J Menzel, et al. Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses. Cancer Lett. 1998 Sep 11;131 (1) :3-11.|[2]Evison M, et al. Human recombinant hyaluronidase (Cumulase) improves intracytoplasmic sperm injection survival and fertilization rates. Reprod Biomed Online. 2009 Jun;18 (6) :811-4. |[3]Gao X, et al. Mechanistic Modeling of the Effect of Recombinant Human Hyaluronidase (rHuPH20) on Subcutaneous Delivery of Cetuximab in Rats. Pharm Res. 2022 Aug;39 (8) :1867-1880.
Shipping Conditions
Isolate blue ice and the product with bubble pack to avoid direct contact
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Enzyme
Clinical Information
Launched
Citation 01
Adv Mater. 2025 Nov 28:e18378.|Animals (Basel) . 2025 Nov 16;15 (22) :3304.|Cell Death Dis. 2025 Mar 20;16 (1) :190.|Preprints. 2025 Nov 26.|Adv Sci (Weinh) . 2025 Apr 3:e2412356.|Cancer Res. 2025 Aug 1;85 (15) :2805-2819.|Cell Biosci. 2023 Aug 10;13 (1) :147.|Cell Oncol (Dordr) . 2024 Dec;47 (6) :2439-2460.|Drug Dev Ind Pharm. 2023 Feb;49 (2) :189-206.|Int J Mol Sci. 2025 Nov 27;26 (23) :11475.|Mol Cancer. 2024 Jan 10;23 (1) :12.|Nat Commun. 2023 May 26;14 (1) :3050.|Theranostics. 2023 Mar 27;13 (6) :2040-2056.